DIL vs Gujarat Kidney vs Sakar Healthcare: Which Stock Should You Track
- October 16, 2026
- Posted by: Chaitanya Auti
- Category: Market
DIL PE 27.21, mkt cap Rs 1,583 crore. Gujarat Kidney and Super Speciality PE 85.50, mkt cap Rs 1,429 crore. Sakar Healthcare PE 61.80, mkt cap Rs 2,230 crore.
Quick Answer
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, DIL carries a market capitalisation of about Rs 1,583 crore, against Rs 1,429 crore for Gujarat Kidney and Super Speciality and Rs 2,230 crore for Sakar Healthcare, with return on equity of 17.67%, 6.14% and 9.40% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare: Company Overview
DIL is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,583 crore, a return on equity of 17.67% and a book value of Rs 138.15 per share. Its quarterly revenue moved from Rs 145.03 crore in June 2025 to Rs 126.19 crore in June 2026, a change of -13.0%.
Gujarat Kidney and Super Speciality is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,429 crore, a return on equity of 6.14% and a book value of Rs 32.03 per share. Its quarterly revenue moved from Rs 15.27 crore in June 2025 to Rs 34.98 crore in June 2026, a change of +129.1%.
Sakar Healthcare is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,230 crore, a return on equity of 9.40% and a book value of Rs 145.82 per share. Its quarterly revenue moved from Rs 53.13 crore in June 2025 to Rs 74.51 crore in June 2026, a change of +40.2%.
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare: Valuation and Profitability Snapshot
| Metric | DIL | Gujarat Kidney and Super Speciality | Sakar Healthcare |
|---|---|---|---|
| Market Cap (approx.) | Rs 1,583 crore | Rs 1,429 crore | Rs 2,230 crore |
| PE Ratio (TTM) | 27.21 | 85.50 | 61.80 |
| PB Ratio | 3.89 | 5.66 | 6.87 |
| Return on Equity (ROE) | 17.67% | 6.14% | 9.40% |
| EPS (TTM, Rs) | 19.77 | 2.12 | 16.22 |
| Dividend Yield | 0.68% | 0.00% | 0.00% |
| Debt to Equity | 0.28 | 0.12 | 0.17 |
| Book Value per Share (Rs) | 138.15 | 32.03 | 145.82 |
Check the Univest Screener for Live Data
On valuation, DIL trades at a PE of 27.21 and a PB of 3.89, Gujarat Kidney and Super Speciality at a PE of 85.50 and a PB of 5.66, while Sakar Healthcare trades at a PE of 61.80 and a PB of 6.87. On return on equity, the three post 17.67%, 6.14% and 9.40% respectively, and on dividend yield they stand at 0.68%, 0.00% and 0.00%. Sakar Healthcare has the highest market capitalisation of the three at Rs 2,230 crore, while Gujarat Kidney and Super Speciality has the lowest at Rs 1,429 crore. Gujarat Kidney and Super Speciality has the highest PE ratio of the three at 85.50, while DIL has the lowest at 27.21. DIL has the highest return on equity of the three at 17.67%, while Gujarat Kidney and Super Speciality has the lowest at 6.14%. DIL has the highest debt to equity ratio of the three at 0.28, while Gujarat Kidney and Super Speciality has the lowest at 0.12. Debt to equity is 0.28, 0.12 and 0.17 for the three respectively.
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| DIL | Rs 126.19 crore | Rs 9.53 crore | -13.0% | -0.4% | -55.9% |
| Gujarat Kidney and Super Speciality | Rs 34.98 crore | Rs 5.32 crore | +129.1% | +11.8% | -1.5% |
| Sakar Healthcare | Rs 74.51 crore | Rs 10.28 crore | +40.2% | +4.5% | +120.1% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | DIL | Gujarat Kidney and Super Speciality | Sakar Healthcare |
|---|---|---|---|
| June 2025 | Rs 145.03 crore | Rs 15.27 crore | Rs 53.13 crore |
| September 2025 | Rs 135.65 crore | Rs 13.02 crore | Rs 58.77 crore |
| December 2025 | Rs 140.48 crore | Rs 23.31 crore | Rs 70.85 crore |
| March 2026 | Rs 126.64 crore | Rs 31.29 crore | Rs 71.27 crore |
| June 2026 | Rs 126.19 crore | Rs 34.98 crore | Rs 74.51 crore |
Quarterly net profit (Rs crore)
| Quarter | DIL | Gujarat Kidney and Super Speciality | Sakar Healthcare |
|---|---|---|---|
| June 2025 | Rs 21.60 crore | Rs 5.40 crore | Rs 4.67 crore |
| September 2025 | Rs 18.03 crore | Rs 2.88 crore | Rs 4.54 crore |
| December 2025 | Rs 12.02 crore | Rs 3.71 crore | Rs 10.25 crore |
| March 2026 | Rs 18.60 crore | Rs 4.83 crore | Rs 11.02 crore |
| June 2026 | Rs 9.53 crore | Rs 5.32 crore | Rs 10.28 crore |
DIL reported revenue of Rs 145.03 crore in June 2025 and Rs 126.19 crore in June 2026, a change of -13.0% across the period. Its highest quarterly revenue in this window was Rs 145.03 crore in June 2025. Net profit stood at Rs 9.53 crore in June 2026, which is a net profit margin of 7.55%.
Gujarat Kidney and Super Speciality reported revenue of Rs 15.27 crore in June 2025 and Rs 34.98 crore in June 2026, a change of +129.1% across the period. Its highest quarterly revenue in this window was Rs 34.98 crore in June 2026. Net profit stood at Rs 5.32 crore in June 2026, which is a net profit margin of 15.21%.
Sakar Healthcare reported revenue of Rs 53.13 crore in June 2025 and Rs 74.51 crore in June 2026, a change of +40.2% across the period. Its highest quarterly revenue in this window was Rs 74.51 crore in June 2026. Net profit stood at Rs 10.28 crore in June 2026, which is a net profit margin of 13.80%.
Download the Univest iOS App or Univest Android App to track DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare
What is the market cap difference between DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare?
Ans. As of October 2026, DIL has a market cap of approximately Rs 1,583 crore, Gujarat Kidney and Super Speciality is at approximately Rs 1,429 crore, and Sakar Healthcare is at approximately Rs 2,230 crore. Sakar Healthcare is the largest of the three, and its market capitalisation is about 1.6 times that of Gujarat Kidney and Super Speciality, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare comparison.
What are the PE and PB ratios of DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare?
Ans. As of October 2026, the PE ratios stand at 27.21, 85.50 and 61.80 respectively, and the price to book ratios stand at 3.89, 5.66 and 6.87 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and healthcare and against each company’s own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.
Which of the three has the highest ROE?
Ans. DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare post ROE of 17.67%, 6.14% and 9.40% respectively as of October 2026. DIL has the highest return on equity of the three at 17.67%, while Gujarat Kidney and Super Speciality has the lowest at 6.14%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare figures.
Which of these three stocks pays the highest dividend yield?
Ans. DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare carry dividend yields of 0.68%, 0.00% and 0.00% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.
What is the debt to equity ratio for DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare?
Ans. DIL carries a debt to equity of 0.28, Gujarat Kidney and Super Speciality of 0.12, and Sakar Healthcare of 0.17. DIL has the highest debt to equity ratio of the three at 0.28, while Gujarat Kidney and Super Speciality has the lowest at 0.12. The debt to equity ratio compares total borrowings with shareholders’ funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and healthcare need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare comparison.
What were the latest quarterly revenue and net profit of DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare?
Ans. For Q1 FY27 (quarter ended June 2026), DIL reported revenue of Rs 126.19 crore and net profit of Rs 9.53 crore, Gujarat Kidney and Super Speciality reported revenue of Rs 34.98 crore and net profit of Rs 5.32 crore, and Sakar Healthcare reported revenue of Rs 74.51 crore and net profit of Rs 10.28 crore. Compared with the quarter ended June 2025, revenue changed by -13.0% for DIL, +129.1% for Gujarat Kidney and Super Speciality and +40.2% for Sakar Healthcare. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare results.
Does this comparison recommend one of DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and healthcare, it also helps to look at factors such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. Reading the latest filings and investor presentations of DIL, Gujarat Kidney and Super Speciality and Sakar Healthcare directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in DIL vs Gujarat Kidney and Super Speciality vs Sakar Healthcare.